Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 13;29(12):9813-9825.
doi: 10.3390/curroncol29120771.

Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma

Stephanie M Woo  1 , Alexandra V Kimchy  2 , Lynette M Sequeira  3 , Charles S Dorris  4 , Aiwu R He  5 , Amol S Rangnekar  6
Affiliations
Review

Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma

Stephanie M Woo et al. Curr Oncol. .

Abstract

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide, and its incidence has increased rapidly in the United States over the past two decades. Liver transplant is considered curative, but is not always possible, and pre-transplant immunotherapy is of great interest as a modality for downstaging the tumor burden. We present a review of the literature on pre-liver transplant immunotherapy use in patients with HCC. Our literature search queried publications in Ovid MEDLINE, Ovid Embase, and Web of Science, and ultimately identified 24 original research publications to be included for analysis. We found that the role of PD-1 and PD-L1 in risk stratification for rejection is of special interest to researchers, and ongoing randomized clinical trials PLENTY and Dulect 2020-1 will provide insight into the role of PD-1 and PD-L1 in liver transplant management in the future. This literature search and the resulting review represents the most thorough collection, analysis, and presentation of the literature on the subject to date.

Keywords: hepatocellular carcinoma; immunosuppression; immunotherapy; liver cancer; liver transplant.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Twomey J.D., Zhang B. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS J. 2021;23:39. doi: 10.1208/s12248-021-00574-0. - DOI - PMC - PubMed
    1. Lipson E.J., Drake C.G. Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. Clin. Cancer Res. 2011;17:6958–6962. doi: 10.1158/1078-0432.CCR-11-1595. - DOI - PMC - PubMed
    1. Farkona S., Diamandis E.P., Blasutig I.M. Cancer Immunotherapy: The Beginning of the End of Cancer? BMC Med. 2016;14:73. doi: 10.1186/s12916-016-0623-5. - DOI - PMC - PubMed
    1. Reig M., Forner A., Rimola J., Ferrer-Fàbrega J., Burrel M., Garcia-Criado Á., Kelley R.K., Galle P.R., Mazzaferro V., Salem R., et al. BCLC Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 Update. J. Hepatol. 2022;76:681–693. doi: 10.1016/j.jhep.2021.11.018. - DOI - PMC - PubMed
    1. Brar G., Kesselman A., Malhotra A., Shah M.A. Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. JCO Oncol. Pract. 2022;18:35–41. doi: 10.1200/OP.21.00227. - DOI - PubMed

MeSH terms